Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Biological: BI 836858 (BAML-16-001-S2)Drug: ZE46-0134 (BAML-16-001-S21)Other: Laboratory Biomarker AnalysisDrug: AG-221 (BAML-16-001-S3)Drug: AG-120 (BAML-16-001-S16)Drug: AZD5153 (BAML-16-001-S10)Drug: TP-0903 (BAML-16-001-S14)Drug: AZD5991 (BAML-16-001-S18)Drug: SNDX-5613 (BAML-16-001-S17)
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Beat AML, LLC
- Target Recruit Count
- 2000
- Registration Number
- NCT03013998
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
News
No news found